Natera, Inc. (NTRA)
NASDAQ$150.87
Market Cap
$20.4B
Sector
Healthcare
Industry
Medical—Diagnostics & Research
Rank in Sector
742 of 924
Rank in Industry
41 of 49
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
NTRA Insider Trading Activity
NTRA Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $167,447,842 | 137 | 100 |
Related Transactions
| Chapman Rowan E | director | 0 | $0 | 3 | $1.16M | $-1.16M |
| Marcus Gail Boxer | director | 0 | $0 | 5 | $2.86M | $-2.86M |
| Baynes Roy D. | director | 0 | $0 | 1 | $5.44M | $-5.44M |
| Fesko John | PRESIDENT, CHIEF BUS. OFFICER | 0 | $0 | 15 | $5.64M | $-5.64M |
| RABINOWITZ DANIEL | SEC. AND CHIEF LEGAL OFFICER | 0 | $0 | 14 | $9.74M | $-9.74M |
| BOTHA ROELOF | director | 0 | $0 | 1 | $14.79M | $-14.79M |
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | 0 | $0 | 17 | $15.52M | $-15.52M |
| Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | 0 | $0 | 33 | $17M | $-17M |
| Sheena Jonathan | CO-FOUNDER | 0 | $0 | 21 | $19.21M | $-19.21M |
| Rabinowitz Matthew | EXECUTIVE CHAIRMAN | 0 | $0 | 6 | $35.73M | $-35.73M |
| Chapman Steven Leonard | CEO AND PRESIDENT | 0 | $0 | 21 | $40.36M | $-40.36M |
About Natera, Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro …
Insider Activity of Natera, Inc.
Over the last 12 months, insiders at Natera, Inc. have bought $0 and sold $167.45M worth of Natera, Inc. stock.
On average, over the past 5 years, insiders at Natera, Inc. have bought $3.98M and sold $94.95M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 219,820 shares for transaction amount of $6.32M was made by Rabinowitz Matthew () on 2022‑05‑12.
List of Insider Buy and Sell Transactions, Natera, Inc.
| 2025-03-18 | Sale | Sheena Jonathan | CO-FOUNDER | 5,700 0.0042% | $145.61 | $829,979 | +3.61% | |
| 2025-03-17 | Sale | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | 1,127 0.0008% | $146.04 | $164,584 | +3.31% | |
| 2025-03-17 | Sale | Sheena Jonathan | CO-FOUNDER | 181 0.0001% | $146.03 | $26,431 | +3.32% | |
| 2025-03-17 | Sale | RABINOWITZ DANIEL | SEC. AND CHIEF LEGAL OFFICER | 928 0.0007% | $146.04 | $135,521 | +3.31% | |
| 2025-03-17 | Sale | Chapman Steven Leonard | CEO AND PRESIDENT | 6,702 0.0049% | $146.03 | $978,678 | +3.32% | |
| 2025-03-17 | Sale | Fesko John | PRESIDENT, CHIEF BUS. OFFICER | 795 0.0006% | $146.04 | $116,099 | +3.31% | |
| 2025-03-17 | Sale | Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | 1,026 0.0007% | $146.04 | $149,836 | +3.31% | |
| 2025-03-17 | Sale | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | 792 0.0006% | $146.04 | $115,661 | +3.31% | |
| 2025-03-14 | Sale | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | 50,000 0.0369% | $147.71 | $7.39M | +0.69% | |
| 2025-03-12 | Sale | Marcus Gail Boxer | director | 1,014 0.0008% | $145.86 | $147,907 | +2.57% | |
| 2025-03-12 | Sale | Marcus Gail Boxer | director | 4,000 0.003% | $147.69 | $590,773 | +2.57% | |
| 2025-03-05 | Sale | Chapman Steven Leonard | CEO AND PRESIDENT | 87,272 0.0626% | $143.40 | $12.52M | -2.98% | |
| 2025-03-05 | Sale | Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | 6,000 0.0043% | $143.29 | $859,734 | -2.98% | |
| 2025-02-26 | Sale | Sheena Jonathan | CO-FOUNDER | 5,600 0.0042% | $160.47 | $898,609 | -10.45% | |
| 2025-02-06 | Sale | Fesko John | PRESIDENT, CHIEF BUS. OFFICER | 663 0.0005% | $177.77 | $117,862 | -11.05% | |
| 2025-02-06 | Sale | Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | 1,632 0.0012% | $177.77 | $290,121 | -11.05% | |
| 2025-02-03 | Sale | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | 43,502 0.0329% | $176.88 | $7.69M | -11.30% | |
| 2025-01-31 | Sale | Sheena Jonathan | CO-FOUNDER | 163 0.0001% | $176.60 | $28,786 | -10.98% | |
| 2025-01-31 | Sale | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | 2,286 0.0017% | $175.98 | $402,288 | -10.98% | |
| 2025-01-31 | Sale | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | 1,886 0.0014% | $176.60 | $333,068 | -10.98% |
Total: 676
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Rabinowitz Matthew | EXECUTIVE CHAIRMAN | 2364288 1.7489% | $356.7M | 1 | 74 | +52.44% |
| BOTHA ROELOF | director | 1224787 0.906% | $184.78M | 2 | 2 | +4.55% |
| HEALY JAMES | director | 0 0% | $0 | 3 | 2 | <0.0001% |
| Steuart John | director | 0 0% | $0 | 1 | 1 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$53,318,456 | 175 | 15.57% | $439.27M | |
$38,597,637 | 114 | 658.88% | $2.09M | |
$1,590,764 | 16 | 3.90% | $51.8M | |
Natera, Inc. (NTRA) | $26,663,659 | 7 | -12.13% | $20.4B |
$151,252 | 6 | -58.10% | $23.96M |
NTRA Institutional Investors: Active Positions
| Increased Positions | 323 | +56.77% | 17M | +14% |
| Decreased Positions | 256 | -44.99% | 13M | -10.88% |
| New Positions | 137 | New | 3M | New |
| Sold Out Positions | 43 | Sold Out | 579,247 | Sold Out |
| Total Postitions | 636 | +11.78% | 127M | +3.12% |
NTRA Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Vanguard Group Inc | $1.83M | 9.12% | 12.32M | +879,463 | +7.69% | 2024-12-31 |
| Blackrock, Inc. | $1.36M | 6.8% | 9.18M | +947,457 | +11.51% | 2024-12-31 |
| Price T Rowe Associates Inc /Md/ | $999,363.00 | 4.99% | 6.74M | +4M | +134.88% | 2024-12-31 |
| Jpmorgan Chase & Co | $993,285.00 | 4.96% | 6.7M | +2M | +44.68% | 2024-12-31 |
| Farallon Capital Management Llc | $656,853.00 | 3.28% | 4.43M | -125,700 | -2.76% | 2024-12-31 |
| Duquesne Family Office Llc | $528,679.00 | 2.64% | 3.57M | 0 | 0% | 2024-12-31 |
| Wellington Management Group Llp | $480,239.00 | 2.4% | 3.24M | +439,778 | +15.71% | 2024-12-31 |
| Fred Alger Management, Llc | $447,301.00 | 2.24% | 3.02M | -994,184 | -24.78% | 2024-12-31 |
| State Street Corp | $443,322.00 | 2.22% | 2.99M | -503,369 | -14.4% | 2024-12-31 |
| Rtw Investments, Lp | $384,382.00 | 1.92% | 2.59M | 0 | 0% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.